Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

Author

HOME, Philip D¹ ; POCOCK, Stuart J² ; BECK-NIELSEN, Henning³ ; CURTIS, Paula S⁴ ; GOMIS, Ramon⁵ ; HANEFELD, Markolf⁶ ; JONES, Nigel P⁷ ; KOMAJDA, Michel⁸ ; MCMURRAY, John J. V⁹
[1] Newcastle Diabetes Centre and Newcastle University, Newcastle upon Tyne, United Kingdom
[2] Medical Statistics Unit, London School of Hygiene andTropical Medicine, London, United Kingdom
[3] Department of Endocrinology and Metabolism, Odense, Denmark
[4] GlaxoSmithKline Research and Development, Greenford, United Kingdom
[5] University of Barcelona, Barcelona, Spain
[6] Zentrum für Klinische Studien Forschungsbereich Endokrinologie und Stoffwechsel, Dresden, Germany
[7] GlaxoSmithKline Research and Development, Harlow, United Kingdom
[8] Université Pierre et Marie Curie Paris 6; Hôpital Pitié-Salpêtrière, Département de Cardiologie, Paris, France
[9] British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom
RECORD Study Team

Source

Lancet (British edition). 2009, Vol 373, Num 9681, pp 2125-2135, 11 p ; ref : 27 ref

CODEN

LANCAO

ISSN

0140-6736

Scientific domain

General medicine general surgery

Publisher

Elsevier, Kidlington

Publication country

United Kingdom

Document type

Article

Language

English

Keyword (fr)

Association médicamenteuse Diabète de type 2 Essai clinique Etude multicentrique Hypoglycémiant Médecine Médicament Pathologie de l'appareil circulatoire Pronostic Randomisation Rosiglitazone Traitement associé Voie orale Essai ouvert Essai thérapeutique Dérivé de la thiazolidinedione Endocrinopathie Maladie métabolique

Keyword (en)

Drug combination Type 2 diabetes Clinical trial Multicenter study Hypoglycemic agent Medicine Drug Cardiovascular disease Prognosis Randomization Rosiglitazone Combined treatment Oral administration Thiazolidinedione derivatives Endocrinopathy Metabolic diseases

Keyword (es)

Asociación medicamentosa Diabetes de tipo 2 Ensayo clínico Estudio multicéntrico Hipoglicemiante Medicina Medicamento Aparato circulatorio patología Pronóstico Aleatorización Rosiglitazona Tratamiento asociado Vía oral Tiazolidinediona derivado Endocrinopatía Metabolismo patología

Classification

Pascal

002 Biological and medical sciences / 002B Medical sciences / 002B01 General aspects

Pascal

002 Biological and medical sciences / 002B Medical sciences / 002B21 Endocrinopathies / 002B21E Endocrine pancreas. Apud cells (diseases) / 002B21E01 Diabetes. Impaired glucose tolerance / 002B21E01A Etiopathogenesis. Screening. Investigations. Target tissue resistance

Discipline

Endocrinopathies Generalities in medical sciences

Origin

Inist-CNRS

Database

PASCAL

INIST identifier

21614788

Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS